Lilly could obtain approval for a weight loss pill that would unlock even more growth. Investors should never ignore valuations when picking stocks. The price a stock trades at can drastically ...

Approval for orforglipron would not only generate a lot of bullishness for the healthcare stock, but would also provide Eli Lilly with yet another blockbuster drug, and potentially enable it to ...

Eli Lilly (NYSE: LLY) stock inched 2.5% higher through 9:50 a.m. ET Thursday after beating on the top and bottom lines in this morning's Q4 earnings report. Heading into the report, analysts ...

Today's Research Daily features new research reports on 16 major stocks, including Apple Inc. (AAPL), Eli Lilly and Co. (LLY) and Shopify Inc. (SHOP), as well as a micro-cap stock ImmuCell Corp ...

Eli Lilly continues to see strong growth coming from its GLP-1 drugs. The company's current 2025 guidance looks conservative. The stock is reasonably valued given the growth opportunities in front ...

Revenue from Zepbound leapt to $1.91 billion, up from $175.8 million a year earlier. Mounjaro's revenue rose to $3.53 billion. Lilly's stock climbed more than 2% Thursday morning.

On Wednesday, Erste Group analysts upgraded Eli Lilly stock from Hold to Buy, citing a robust product demand and a promising pipeline of potential successes. The analysts highlighted the ...

Shares of Eli Lilly & Co. LLY slid 3.00% to $844.27 Friday, on what proved to be an all-around grim trading session for the stock market, with the S&P 500 Index SPX falling 0.01% to 6,114.63 and ...

With its 2-star rating, we believe Eli Lilly’s stock is over-valued compared to our long-term fair value estimate. We are maintaining our Eli Lilly fair value estimate at $580. Mounjaro and ...

Eli Lilly's stock rose 3.3% on Feb. 6 after a strong Q4 earnings report. The company reported a 45% year-over-year increase in revenue, reaching $13.5 billion, driven by significant sales of its ...